Neumora, ambitious startup focused on neuroscience, considers filing for an IPO

Neumora Therapeutics, the neuroscience company launched last year in a bid to revitalize a field much of pharma abandoned, is raising a crossover round and considering filing for an IPO this summer, according to two sources with knowledge of the situation.

A Neumora spokesperson declined to comment, citing company policy “to not comment on financing plans or timelines.”

Neumora was created by ARCH Venture Partners and other prominent venture capital firms to reignite the development of new treatments for brain disorders, including anxiety, autism, eating disorders, and neurodegenerative disorders like Alzheimer’s disease. To do this, ARCH decided to go big: It rolled up several existing companies to create Neumora and gave the project the codename RBNC Therapeutics, or Really Big Neuroscience Company. The company raised a $500 million Series A round, including $100 million from Amgen.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In